# Attention-Deficit/Hyperactivity Disorder FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/attention-deficit-hyperactivity-disorder

> No upcoming FDA catalysts in Attention-Deficit/Hyperactivity Disorder; 5 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for Attention-Deficit/Hyperactivity Disorder?

No upcoming FDA catalysts in Attention-Deficit/Hyperactivity Disorder; 5 past events are recorded. SEC Form 8-K: "On September 21, 2026, the Company announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the Company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD)." [Calendar and source filings](https://sec-api.dev/indications/attention-deficit-hyperactivity-disorder)

Source: SEC Form 8-K, accession 0001193125-26-396065, https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-20260921.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/indications/attention-deficit-hyperactivity-disorder#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 14, 2025 | [PTR (ptr) NDA/BLA acceptance](https://sec-api.dev/pdufa/ptr) | CING | Attention-Deficit/Hyperactivity Disorder | completed | "CITY, Kan., October 14, 2025 — Cingulate Inc. (NASDAQ: CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 (dexmethylphenidate), the company's lead candidate for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315225017931/ex99-1.htm)) |
| June 2, 2026 | [PTR (ptr) complete response letter (CRL)](https://sec-api.dev/pdufa/ptr) | CING | Attention Deficit/Hyperactivity Disorder | completed, complete response letter | "CITY, Kan., June 2, 2026 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter for its New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/ex99-1.htm)) |
| September 2026 | [Viloxazine extended-release capsules primary completion](https://sec-api.dev/pdufa/viloxazine-extended-release) | SUPN | Attention-Deficit/Hyperactivity Disorder | delayed | "NCT02736656 (Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02736656)) |
| Sep to Dec 2026 | [Viloxazine extended-release capsules topline data readout](https://sec-api.dev/pdufa/viloxazine-extended-release) | SUPN | Attention-Deficit/Hyperactivity Disorder | scheduled | "NCT02736656 (Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02736656)) |
| September 21, 2026 | [Neuropeptide topline data readout](https://sec-api.dev/pdufa/neuropeptide) | ALKS | attention-deficit hyperactivity disorder | completed, positive | "On September 21, 2026, the Company announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the Company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-20260921.htm)) |

## Drugs

- [PTR (ptr)](https://sec-api.dev/pdufa/ptr) (CING)
- [Viloxazine extended-release capsules](https://sec-api.dev/pdufa/viloxazine-extended-release) (SUPN)
- [Neuropeptide](https://sec-api.dev/pdufa/neuropeptide) (ALKS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/attention-deficit-hyperactivity-disorder.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Attention-Deficit/Hyperactivity Disorder FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/attention-deficit-hyperactivity-disorder

```bibtex
@misc{secapidev_indications_attention_deficit_hyperactivity_disorder_20261116,
  title        = {Attention-Deficit/Hyperactivity Disorder FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/attention-deficit-hyperactivity-disorder}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_attention_deficit_hyperactivity_disorder_20261116","title":"Attention-Deficit/Hyperactivity Disorder FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/attention-deficit-hyperactivity-disorder","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
